Albert W. Gianchetti
Algemeen Directeur bij Xylocor Therapeutics, Inc.
Actieve functies van Albert W. Gianchetti
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Xylocor Therapeutics, Inc.
 Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Directeur/Bestuurslid | - | - |
| Algemeen Directeur | - | - | |
| President | - | - |
Loopbaan van Albert W. Gianchetti
Eerdere bekende functies van Albert W. Gianchetti
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| VANDA PHARMACEUTICALS INC. | Corporate Officer/Principal | 25-10-2007 | 01-12-2008 |
| GSK PLC | Corporate Officer/Principal | - | - |
Opleiding van Albert W. Gianchetti
| University of Delaware | Undergraduate Degree |
| Drexel University | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 5 |
| Verenigd Koninkrijk | 2 |
Operationeel
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| VANDA PHARMACEUTICALS INC. | Health Technology |
| GSK PLC | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Health Technology |
